Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of NEOD001 in AL Amyloidosis (PRONTO OLE)
2016-004664-18Phase 2Terminated
- Sponsor
- Prothena Corporation
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of birtamimab in light-chain amyloidosis, sponsored by Prothena Corporation. Primary endpoints: Long-term safety of NEOD001 and Long-term efficacy of NEOD001. Started May 2017; status: terminated.
02
Drugs
birtamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2016-004664-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004664-18.